Tested Chi-BEAM vs BEAM before stem cell transplant for lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 3 study compares two chemotherapy schedules (Chi-BEAM vs BEAM) given before an autologous stem cell transplant to treat newly diagnosed peripheral T-cell lymphoma that responded to first-line treatment. If you fit the lab and heart/lung requirements, it may offer access to a new treatment approach designed to improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed peripheral T-cell lymphoma, not ALK-positive, and it improved (complete or partial response) after first treatment
- You are 18–65 years old and can provide written informed consent
- Your kidneys, liver, and lungs meet specific lab and breathing test thresholds
- Your heart function is strong enough (left heart pumping ability) and you do not have certain heart rhythm problems
- Your blood counts are high enough (white cells, platelets, and hemoglobin), and your stem cell collection has enough CD34 cells
- You do not have certain conditions like lymphoma in the brain or active hepatitis, HIV, or uncontrolled infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (bendamustine, chidamide, and lenalidomide) for patients with peripheral T-cell lymphoma that has come back or not responded to treatment. It aims to see if this new combination can help when standard treatments have failed.
This trial tests a new approach that combines radiation therapy, a stem cell transplant, and a special immune cell treatment (CAR-T) for people with an aggressive type of B-cell lymphoma that has returned or stopped responding to standard treatments. The goal is to see if this powerful combination can help control the cancer better.
This trial tests a stem cell transplant with a special chemo combination (TEAM) to see if it can prevent lymphoma from coming back in the brain or spinal cord for people with high-risk non-Hodgkin lymphoma.
This study tests a modified chemotherapy “conditioning” plan before an autologous stem cell transplant for people with non-Hodgkin lymphoma. It aims to improve how patients tolerate and recover from the transplant process.
This trial is testing a new treatment for people with a type of lymphoma (DLBCL) that has not gone away or has come back. It combines a study drug called pirtobrutinib with a common chemotherapy regimen (BEAM) before a stem cell transplant, and the goal is to see if this approach is safe and effective in helping patients get to transplant.
This trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to the standard BEAM chemotherapy before a stem cell transplant can help people with relapsed Hodgkin lymphoma. It's for patients who are eligible for a transplant and have stable organ function.
Hear when a new Newly Diagnosed Peripheral T-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.